Previous Page  9 / 14 Next Page
Information
Show Menu
Previous Page 9 / 14 Next Page
Page Background

Page 33

Cell and Gene Therapy 2018 & Clinical Microbiology Congress 2018

Biomedical Research

|

ISSN: 0976-1683

|

Volume 29

S e p t e m b e r 1 0 - 1 1 , 2 0 1 8 | D u b l i n , I r e l a n d

allied

academies

Joint Event on

CLINICAL AND MEDICAL MICROBIOLOGY

CELL AND GENE THERAPY

&

World Congress on

International Conference on

Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C3-008

TARGETING BACTERIAL VIRULENCE TO DEVELOP EVOLUTION PROOF

ANTIBIOTICS

Veerendra Koppolu

AstraZeneca/MedImmune, USA

K

eeping the antibiotic resistance in mind, it is of greatest need to develop new ways to treat bacterial infections. Evolution-

proof antibiotics that disarm the bacterial pathogens without impacting their survival would be an important strategy towards

sidestepping the evolution of resistance. Drugs that disarm the pathogen will generate much weaker selection for resistance than

traditional antibiotics. Disarming the pathogens is possible by targeting a family of bacterial proteins called AraC family proteins

that regulate the bacteria’s ability to infect or damage a host, rather than its ability to survive. We tested this exciting hypothesis

against Shigella flexneri, a diarrhea causing bacterial pathogen responsible for causing 165 million cases of illness and more

than 1.1 million deaths worldwide. We successfully identified several molecules that selectively inhibited an important Shigella

protein VirF that is crucial for causing infection. The highly potent molecule SE-1 is found to not impact the growth of the bacteria

but prevent bacteria’s ability to invade and infect cultured human intestinal cells. SE-1 also inhibits infection pathways in other

pathogenic bacteria that cause infections such as diarrhea, pneumonia, and cholera and thus can be developed as a novel agent

to treat multiple infections. Targeting such infection pathways may yield non-traditional antibiotics that are more powerful and

versatile than our current antimicrobials and would solve the antibiotic resistance issue that has grown to alarming levels.